Selexis, a Swiss-based biotechnology company has established a U.S.-based subsidiary, Selexis Inc., in Marlboro.
Along with the establishment of Selexis Inc., the company has also made Andrew F. Sandford vice president of business development and licensing.
Before joining Selexis, Sandford was with the Dow Chemical Co.’s ventures business unit.
Selexis is a privately held company that develops gene technology for drug discovery, research and manufacturing.
